Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Surmodics Inc (SRDX)

Surmodics Inc (SRDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 376,115
  • Shares Outstanding, K 14,236
  • Annual Sales, $ 132,580 K
  • Annual Income, $ -1,540 K
  • 60-Month Beta 1.01
  • Price/Sales 2.90
  • Price/Cash Flow 34.43
  • Price/Book 3.15
Trade SRDX with:

Options Overview Details

View History
  • Implied Volatility 58.84% ( +1.64%)
  • Historical Volatility 33.64%
  • IV Percentile 41%
  • IV Rank 51.10%
  • IV High 80.60% on 04/17/23
  • IV Low 36.09% on 05/19/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 2.25
  • Today's Open Interest 104
  • Open Int (30-Day) 91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.36
  • Number of Estimates 2
  • High Estimate -0.36
  • Low Estimate -0.36
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.25 +0.19%
on 04/15/24
29.78 -11.69%
on 03/28/24
-1.87 (-6.64%)
since 03/15/24
3-Month
26.25 +0.19%
on 04/15/24
37.50 -29.87%
on 01/31/24
-7.20 (-21.49%)
since 01/16/24
52-Week
16.79 +56.64%
on 05/25/23
39.41 -33.27%
on 09/11/23
+2.77 (+11.77%)
since 04/14/23

Most Recent Stories

More News
SurModics: Fiscal Q1 Earnings Snapshot

SurModics: Fiscal Q1 Earnings Snapshot

SRDX : 26.26 (-0.61%)
SurModics: Fiscal Q4 Earnings Snapshot

SurModics: Fiscal Q4 Earnings Snapshot

SRDX : 26.26 (-0.61%)
SurModics: Fiscal Q3 Earnings Snapshot

SurModics: Fiscal Q3 Earnings Snapshot

SRDX : 26.26 (-0.61%)
Why Shares of Surmodics Jumped This Week

The company gained FDA marketing approval for a drug-coated balloon that will help clear blocked arteries.

SRDX : 26.26 (-0.61%)
Why Shares of Surmodics Soared on Tuesday

An analyst upgrade gave the stock a boost.

SRDX : 26.26 (-0.61%)
Surmodics (SRDX) Q2 Earnings Top Estimates, FY23 View Revised

Surmodics (SRDX) reports a solid fiscal second-quarter top line on the back of robust Medical Device revenues.

JNJ : 143.95 (-2.47%)
ISRG : 374.33 (-0.80%)
EW : 88.01 (-1.33%)
SRDX : 26.26 (-0.61%)
SurModics (SRDX) Reports Q2 Loss, Tops Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 18.37% and 4.63%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

SRDX : 26.26 (-0.61%)
PODD : 169.06 (-2.81%)
SurModics: Fiscal Q2 Earnings Snapshot

SurModics: Fiscal Q2 Earnings Snapshot

SRDX : 26.26 (-0.61%)
Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March...

SRDX : 26.26 (-0.61%)
Surmodics Announces First Patient Enrolled in PROWL Registry Study Using the Pounceâ„¢ Thrombectomy System

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced enrollment of the first patient in PROWL, the Pounceâ„¢ Thrombectomy System Retrospective...

SRDX : 26.26 (-0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Surmodics is a leading provider of medical device and In Vitro Diagnostics (IVD) technologies to the healthcare industry. It reports through two divisions: Medical Devices & IVD.'The Medical Devices segment comprises surface modification coating technologies to improve access, deliverability, and predictable...

See More

Key Turning Points

3rd Resistance Point 28.08
2nd Resistance Point 27.68
1st Resistance Point 27.05
Last Price 26.26
1st Support Level 26.02
2nd Support Level 25.62
3rd Support Level 24.99

See More

52-Week High 39.41
Fibonacci 61.8% 30.77
Fibonacci 50% 28.10
Last Price 26.26
Fibonacci 38.2% 25.43
52-Week Low 16.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar